WO2025158306 - NOVEL HIGH CONCENTRATION PHESGO FORMULATION
National phase entry is expected:
Publication Number
WO/2025/158306
Publication Date
31.07.2025
International Application No.
PCT/IB2025/050686
International Filing Date
23.01.2025
Title **
[English]
NOVEL HIGH CONCENTRATION PHESGO FORMULATION
[French]
NOUVELLE FORMULATION DE PHESGO À HAUTE CONCENTRATION
Applicants **
INTAS PHARMACEUTICALS LTD.
Inventors
ADHIKARY, Laxmi
SWAMI, Shivraj Kashinath
PATEL, Jatinkumar
KHRISTI, Anandkumar Jitendrabhai
GOSWAMI, Roshan
Priority Data
202421005075
25.01.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1996 | |
| EPO | Filing, Examination, Granting | 11670 | |
| Japan | Filing, Examination, Granting | 1907 | |
| South Korea | Filing, Examination, Granting | 1603 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,916
Contact Us
Abstract[English]
The present invention provides high concentration liquid pharmaceutical formulation of Phesgo comprising antibody, buffer, chelating agent, stabilizer/sugar, surfactant and hyaluronidase enzyme.[French]
La présente invention concerne une formulation pharmaceutique liquide de Phesgo à haute concentration qui contient un anticorps, un tampon, un agent chélateur, un stabilisant/sucre, un tensioactif et une enzyme hyaluronidase.